Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | CASP6 | P55212 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | APEX1 | P27695 | 1/20 | 0.70 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resazurin SCHEMBL8665938 | 1.00 | KMT2A (0.70) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL6338 | 1.00 | KMT2A (0.70) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL10937342 | 0.99 | KMT2A (0.68) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL21823760 | 0.99 | KMT2A (0.68) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL29456662 | 0.99 | KMT2A (0.68) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL5492813 | 0.99 | KMT2A (0.68) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL272629 | 0.99 | KMT2A (0.72) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL10638468 | 0.96 | KMT2A (0.65) | KMT2AMEN1POLBKDM4EMAPK1 | |
| Resazurin SCHEMBL20190032 | 0.87 | APP (0.71) | KMT2AMEN1POLBKDM4EMAPK1 | |
| SCHEMBL17921280 | 0.84 | KMT2A (0.49) | KMT2AMEN1POLBKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241416-A1 | METHODS FOR THE IDENTIFICATION OF SARM1 NADASE ACTIVITY INHIBITORS AND USES THEREOF | UNIV BAR ILAN (US) | 2022-08-04 | — | — | US | claimed |
| WO-2026099345-A1 | LARCH TURPENTINE EMULSION | VEREIN FÜR KREBSFORSCHUNG (CH) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735612-A1 | VIRAL VECTORS FOR TREATING BLADDER DISEASES | EG 427 (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736894-A1 | ANTIMICROBIAL PEPTIDE-FUNCTIONALIZED CROSSLINKABLE COPOLYMER, CROSSLINKED COPOLYMER AND HYDROGEL WITH ANTIBACTERIAL ACTIVITY | Universität Siegen, Körperschaft des öffentlichen Rechts (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026087068-A1 | POLYTHIOPHENE POLYMERS DOPED WITH TETRATRICOPEPTIDE REPEAT PROTEIN | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOMATERIALES - CIC biomaGUNE (ES) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026087600-A1 | STYRYL BENZOTHIAZOLIUM SALTS AND ITS USES AGAINST PARASITIC INFECTIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732907-A1 | STYRYL BENZOTHIAZOLIUM SALTS AND ITS USES AGAINST PARASITIC INFECTIONS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | UAB RES FOUND (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260085333-A1 | BIOCATALYTIC METHOD FOR ENHANCING ARSENIC METHYLATION AND VOLATILIZATION OF CLOSTRIDIUM AND USE THEREOF | INST OF ECO ENVIRONMENTAL AND SOIL SCIENCES GUANGDONG ACADEMY OF SCIENCES (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12570657-B2 | Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-03-10 | — | — | US | disclosed |
| EP-3989989-A1 | INTESTINAL MICROBIOTA BACTERIA AND COMPOSITION CONTAINING SAME FOR USE IN THE PREVENTION AND/OR TREATMENT OF DISEASES CHARACTERISED BY EXCESS 2-HYDROXYGLUTARATE | YSOPIA Biosciences (FR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3989988-A1 | BACTERIUM OF THE CHRISTENSENELLACEAE FAMILY AND COMPOSITION CONTAINING SAME FOR PREVENTING AND/OR TREATING RENAL INSUFFICIENCY | YSOPIA Biosciences (FR) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125826-A1 | Synergism of GOS and polyfructose | N.V. NUTRICIA (NL) | 2022-04-28 | — | — | US | disclosed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022079315-A1 | PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION | ONELIFE S.A. (BE) | 2022-04-21 | — | — | WO | disclosed |
| EP-3360891-B1 | CELL PENETRATING PEPTIDES OF HUMAN ORIGIN | KARLSRUHER INST TECHNOLOGIE (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | GLAS USA LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BT BIDCO LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | THE UNIVERSITY OF TULSA (US) | 2022-02-03 | — | — | US | disclosed |
| CN-107636158-B | Biocatalytic oxidation | 赢创运营有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | HK2, G6PD, GCK | KMT2A 959/4885MEN1 4776/4885POLB 434/4885 |
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | SOD1, CUTA, SOD3 | KMT2A 1874/4885MEN1 2544/4885POLB 108/4885 |
| US-20260085333-A1 | BIOCATALYTIC METHOD FOR ENHANCING ARSENIC METHYLATION AND VOLATILIZATION OF CLOSTRIDIUM AND USE THEREOF | AS3MT, DNMT1, TDO2 | KMT2A 518/4885MEN1 2483/4885POLB 2086/4885 |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | ACKR3, CXCR2, CXCR3 | KMT2A 4459/4885MEN1 1941/4885POLB 2481/4885 |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | KMT2A 3806/4885MEN1 1093/4885POLB 4545/4885 |
| US-12570657-B2 | Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof | TYMP, TK1, DCK | KMT2A 643/4885MEN1 125/4885POLB 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.